Speaking.

In 2024, the Medicines Control Agency seized FDA-approved medications from Innovarx warehouses in The Gambia and shut the company down. It was the third existential threat in eight years — after COVID nearly took us out and after a regulatory framework written for a market that did not exist had paralyzed the sector for half a decade. We rebuilt from each one. We generated $2M in revenue on $740K raised. We served 200,000 patients across five regions of The Gambia. And we wrote and passed the Medicines and Related Products Amendment Act 2025 into law.

This talk is the operator’s account of what it actually takes to build a healthcare company in a frontier market: not the romanticized version, not the despair version, but the granular, practical, hard-earned truth. What capital strategies survive contact with a regulatory shutdown. What kind of leadership composes a team through three years of payroll uncertainty. What you owe the patients who kept showing up when the lights flickered.

The audiences who book this talk are not looking for inspiration porn. They are operators, investors, and policymakers who want to understand what frontier-market resilience actually costs and what it actually returns.

Across The Gambia and the wider West African region, men endure pain in silence. They do not seek care for prostate symptoms, for diabetes that is quietly destroying their kidneys, for hypertension that is rehearsing a stroke. Unless something bleeds or breaks, they do not come in. By the time they do, the diagnosis is often a sentence rather than a problem.

Through Innovarx and the Campeh Jambarr platform, we built a community-health model that meets men where they are — in the language they speak, on the platforms they actually use, with the trust signals that actually move them. The single most-watched piece of health content I have ever produced began with a sentence about prostate symptoms. It reached more than 100,000 men in a country of 2.5 million.

This talk unpacks what it took to build that trust, what we learned about masculinity and care-seeking that does not appear in the global health literature, and how community health programs anywhere — frontier markets, immigrant communities in the West, underserved domestic populations — can adapt the model.

Non-communicable diseases — diabetes, hypertension, cardiovascular disease, cancer — are now the leading cause of death across sub-Saharan Africa, and almost no infrastructure exists to address them at scale. The donor capital chases the communicable disease budgets. The clinical training systems were built for acute care. The patients live and die in the gap.

At Innovarx we built that infrastructure from scratch. The WOW Compass care management platform. The 4-4-12 methodology. The Assurance Care Plan. The CGM-integrated diabetes monitoring program. The standing onboarding protocol for hypertension and diabetes. None of it was theoretical. All of it was built, deployed, and iterated against 200,000 actual patients across five regions of an actual country with an actual regulatory environment.

This talk hands the playbook to the audience. What works, what failed, what we would never repeat. What philanthropic capital should fund and what it absolutely should not. How NCD programs in any resource-constrained setting — frontier markets, rural America, immigrant clinics — can borrow what we learned and skip the mistakes.

There are two voices loudest in the African development conversation, and both of them are lying. One romanticizes the continent into a TED-talk montage where every founder is a hero and every problem is a pitch deck away from solved. The other catastrophizes — every metric is a tragedy, every policy a failure, every entrepreneur a victim of forces too large to name. Young Africans deserve neither.

This talk is the third voice. Hard truth: building anything here is brutal, the systems are broken in ways the global development industry does not understand, and most ventures will fail for reasons that have nothing to do with the founder’s effort. Grounded optimism: the continent is being rebuilt anyway, by people who have made peace with the cost, and the work is more meaningful than anything the easier paths can offer. Both can be true at once. Both must be said in the same sentence.

I deliver this talk to young African audiences and to diaspora returnees who are weighing the move home. It is the talk I wish someone had given me before I started Innovarx in 2015.

Every time another boat goes down in the Mediterranean, the conversation about Africa’s future restarts in the wrong place. The young men dying in that water are not failed migrants — they are a market signal. They are telling us that the continent has not built the future they need fast enough, and that the diaspora has not yet decided whether building it is its responsibility or its option.

I made that decision in 2019 when I returned to The Gambia from the United States to launch Innovarx’s country operation. This talk is the case for that return — economic, generational, and personal — and an honest accounting of what it costs. Not everyone should come home. Those who do should know what they are choosing.

I am developing this keynote for delivery in late 2026 to diaspora professional summits, US–Africa business forums, and African university audiences with significant diaspora populations. Bookers interested in this talk are invited to inquire — early venues will help shape the final form.